Last updated: February 10, 2025
Sponsor: Rush University Medical Center
Overall Status: Suspended
Phase
3
Condition
Inflammation
Male Hormonal Deficiencies/abnormalities
Erectile Dysfunction
Treatment
Rifampin
Gentamicin
Chlorhexidine
Clinical Study ID
NCT06489431
21120903
Male Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Inclusion criteria include all men undergoing penile prosthesis (any manufacturer)implantation (inpatient or outpatient)
Exclusion
Exclusion Criteria:
- Exclusion criteria include men who are having revision implant surgeries, men whomay require intraoperative complex reconstruction including graft for Peyronie'sDisease, and transgender males
Study Design
Total Participants: 100
Treatment Group(s): 3
Primary Treatment: Rifampin
Phase: 3
Study Start date:
December 04, 2023
Estimated Completion Date:
December 31, 2027
Study Description
Connect with a study center
Rush University Medical Center
Chicago, Illinois 60612
United StatesSite Not Available
Uropartners Surgery Center
Des Plaines, Illinois 60018
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.